Walmart shares slide as earnings pressure traces to weaker U.S. pharmaceutical sales, report says

Walmart is facing renewed scrutiny after a report highlighted weakness in its U.S. sales growth, describing the pressure as the biggest issue since 2022. The concern centers on the company’s earnings performance, which the report said was weighed down by slower pharmaceutical results rather than broad-based deterioration across all retail categories.

The post pointed to a specific driver: lagging pharmacy sales that were affected by new federal negotiations intended to bring down drug prices. In the report’s framing, the timing and impact of those policy changes appear to have left Walmart with less sales momentum in the near term than investors had expected.

The broadcast also suggested that the pharmaceutical slowdown is not unique to Walmart, describing it as an issue affecting the broader pricing and negotiation environment around prescription drugs. That matters because pharmacy typically acts as a steady contributor to retail foot traffic and basket size, even when general merchandise demand is choppy.

While Walmart’s results were characterized as disappointing, the report did not provide granular breakdowns such as segment-level sales figures for pharmacy, the size of the pharmaceutical headwind, or how much of the weakness is attributable to timing versus pricing. It also did not specify whether the lag reflects lower unit demand, pricing changes, reimbursement dynamics, or a mix shift within prescriptions.

For readers trying to contextualize the pharmaceutical angle, the key point is that U.S. drug pricing reforms can affect how quickly retailers and pharmacy operators see changes in reimbursement rates and pricing. Even when overall shoppers keep buying essentials, policy-driven adjustments can show up in pharmacy revenue patterns before the company can offset them elsewhere.

Walmart, as a large U.S. retailer with extensive in-store pharmacy services, is exposed to those reimbursement and pricing dynamics. Its investors therefore tend to watch pharmacy for early indicates that can ripple into total comparable sales (sales at stores open at least a year) and earnings trends.

Still, the broadcast did not lay out a detailed path for what management expects next, such as whether pharmacy sales are projected to stabilize as negotiations move from implementation to routine pricing. It also did not clarify whether Walmart expects to face ongoing headwinds or if the issue is largely temporary.

What to watch next is whether Walmart, in its subsequent disclosures, provides a clearer bridge between pharmaceutical performance and the company’s overall sales growth trend. Investors will likely look for any segment detail that quantifies pharmacy’s impact and any guidance that addresses how federal drug pricing negotiations will flow through to future revenue and margin.